PIQ Stock | Chart | Proteomics International Laboratories Limited Stock Price Today, Chart, performance

Short Term Long Term Short Term Comparison Long Term Comparison

PIQ
1d-5.79%
1w-8.80%
1m-8.80%
1y14.00%
PIQ
1y14.00%
5y314.55%
10y0.00%
20y0.00%

Bitcoin
-0.82%
-9.09%
-6.40%
106.24%
Bitcoin
106.24%
1,146.32%
11,770.30%
0.00%

Ethereum
-0.90%
-11.75%
-14.49%
45.57%
Ethereum
45.57%
1,828.08%
0.00%
0.00%

Gold
0.26%
2.56%
11.41%
20.52%
Gold
20.52%
88.92%
85.82%
499.35%

Silver
0.47%
4.25%
15.38%
14.30%
Silver
14.30%
94.94%
48.08%
306.93%

Apple
-2.19%
1.78%
0.04%
5.09%
Apple
5.09%
260.11%
-66.73%
39,041.00%

Amazon
-1.68%
-1.44%
4.92%
78.52%
Amazon
78.52%
96.45%
-43.46%
7,943.96%

Microsoft
-1.96%
-2.97%
-0.67%
45.75%
Microsoft
45.75%
259.81%
923.86%
2,532.12%

S&P 500
-1.20%
-2.84%
-1.08%
22.34%
S&P 500
22.34%
74.12%
171.80%
346.13%

Dow & Jones
-0.65%
-2.95%
-2.53%
11.36%
Dow & Jones
11.36%
42.65%
129.74%
261.03%

ATH

ATH Price$1.35
ATH Date2021-04-16
% since ATH-15.56%
% to ATH18.42%

ATL

ATL Price$0.15
ATL Date2017-05-22
% from ATL686.21%
Last Low Price$0.715
Last Low Date2022-06-22
% From Last Low59.44%

IPO

IPO Price$0.24
% Current ROI USD485.11%
ATH Price$1.35
% ROI ATH 93,103.45%

[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="PIQ"]

Key Data [addtoany]

Current price	$1.14
Sector	Healthcare
Industry	Biotechnology
Today's High/Low	$1.2/$1.135
Volume	313,620.00
Previous Close	$1.21
52 Week High/Low	$1.4/$0.7
Market Cap	158,380,528.00
P/E Ratio	0
Forward P/E 1 Yr.	$0.00
Earnings Per Share(EPS)	$-0.04
Annualized Dividend	$0

$1.14

[addtoany]

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics.
It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia.
The company also offers analytical services, including specialist contract research, analytical, and consultancy.
Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia.
The company was founded in 2001 and is based in Perth, Australia.

Annual Data \| Millions of US $ except per share data	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30
Cash on hand	-	-	-	-	-	-	-	-
Receivables	$0.46	$0.60	$0.21	$0.14	$0.50	$0.21	-	-
Inventory	-	-	-	-	-	-	-	-
Pre-Paid Expenses	-	-	-	-	-	-	-	-
Other Current Assets	$1.19	$0.84	$1.25	$0.87	$0.01	$0.11	-	-
Total Current Assets	$3.24	$3.79	$2.38	$1.60	$2.52	$0.38	-	-
Property, Plant, And Equipment	$0.21	$0.36	$0.51	$0.02	$0905900	$0.02	-	-
Long-Term Investments	$0.16	$1.18	-	-	-	-	-	-
Goodwill And Intangible Assets	-	-	-	-	-	-	-	-
Other Long-Term Assets	$0.16	$0.16	$0.46	-	-	$0100000	-	-
Total Long-Term Assets	$0.38	$1.70	$0.51	$0.02	-	-	-	-
Total Assets	$3.62	$5.49	$2.89	$1.62	$2.53	$0.39	-	-
Total Current Liabilities	$0.55	$0.61	$0.58	$0.37	$0.28	$0.85	-	-
Long Term Debt	-	$0.17	$0.37	$0.44	$0.44	$0.44	-	-
Other Non-Current Liabilities	$0.07	$0.04	$0.04	$0.02	$0.01	-	-	-
Total Long Term Liabilities	$0.09	$0.21	$0.70	$0.46	-	-	-	-
Total Liabilities	$0.63	$0.82	$1.28	$0.83	$0.73	$1.30	-	-
Common Stock Net	$10.54	$10.37	$5.94	$4.05	$4.04	$0.37	-	-
Retained Earnings (Accumulated Deficit)	$-8.26	$-6.18	$-4.74	$-3.83	$-2.50	$-1.35	-	-
Comprehensive Income	-	-	-	-	-	-	-	-
Other Share Holders Equity	$0.71	$0.49	$0.42	$0.57	$0.26	$0.08	-	-
Share Holder Equity	$2.99	$4.68	$1.61	$0.79	$1.81	$-0.90	-	-
Total Liabilities And Share Holders Equity	-	-	-	-	-	-	-	-

Annual Data | Millions of US $ except per share data

2019-06-30

2018-06-30

2017-06-30

2016-06-30

2015-06-30

2014-06-30

2013-06-30

2012-06-30

Cash on hand

Receivables

$0.46

$0.60

$0.21

$0.14

$0.50

$0.21

Inventory

Pre-Paid Expenses

Other Current Assets

$1.19

$0.84

$1.25

$0.87

$0.01

$0.11

Total Current Assets

$3.24

$3.79

$2.38

$1.60

$2.52

$0.38

Property, Plant, And Equipment

$0.21

$0.36

$0.51

$0.02

$0905900

$0.02

Long-Term Investments

$0.16

$1.18

Goodwill And Intangible Assets

Other Long-Term Assets

$0.16

$0.46

$0100000

Total Long-Term Assets

$0.38

$1.70

$0.51

$0.02

Total Assets

$3.62

$5.49

$2.89

$1.62

$2.53

$0.39

Total Current Liabilities

$0.55

$0.61

$0.58

$0.37

$0.28

$0.85

Long Term Debt

$0.17

$0.37

$0.44

Other Non-Current Liabilities

$0.07

$0.04

$0.02

$0.01

Total Long Term Liabilities

$0.09

$0.21

$0.70

$0.46

Total Liabilities

$0.63

$0.82

$1.28

$0.83

$0.73

$1.30

Common Stock Net

$10.54

$10.37

$5.94

$4.05

$4.04

$0.37

Retained Earnings (Accumulated Deficit)

$-8.26

$-6.18

$-4.74

$-3.83

$-2.50

$-1.35

Comprehensive Income

Other Share Holders Equity

$0.71

$0.49

$0.42

$0.57

$0.26

$0.08

Share Holder Equity

$2.99

$4.68

$1.61

$0.79

$1.81

$-0.90

Total Liabilities And Share Holders Equity

Annual Data \| Millions of US $ except per share data	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30
Revenue	$1.47	$1.18	$0.93	$0.82	$0.97	$0.48	$0.68	$0.59
Cost Of Goods Sold	$0.81	$0.67	$0.58	$0.40	$0.33	$0.02	$0.07	$0.01
Gross Profit	-	-	-	-	-	-	-	-
Research And Development Expenses	-	$0.59	$0.59	$0.59	$0.59	$0.18	$0.16	$0.08
SG&A Expenses	$2.38	$1.77	$1.52	$1.85	$0.96	$1.08	$1.23	$0.71
Other Operating Income Or Expenses	$0.67	$0.41	$0.22	$0.25	$0.05	$0954600	-	-
Operating Expenses	$4.54	$3.52	$-6.46	$2.73	$1.48	$1.34	-	-
Operating Income	$-3.07	$-2.35	$7.39	$-1.91	$-0.52	$-0.22	-	-
Total Non-Operating Income/Expense	-	-	-	-	-	-	-	-
Pre-Tax Income	$-2.08	$-1.44	$-0.92	$-1.33	$-1.13	$-0.25	-	-
Income Taxes	-	$0	$0	$0	$0.02	$-0296700	$0900000	$0.09
Income After Taxes	-	$0	$0	$0	$0.02	$-0296700	$0900000	$0.09
Other Income	-	-	-	-	-	-	-	-
Income From Continuous Operations	$-2.08	$-1.44	$-0.92	$-1.33	$-1.15	$-0.25	-	-
Income From Discontinued Operations	-	-	-	-	-	-	-	-
Net Income	$-2.08	$-1.44	$-0.92	$-1.33	$-1.15	$-0.25	-	-
EBITDA	-	-	-	-	-	-	-	-
EBIT	$-3.07	$-2.35	$7.39	$-1.91	$-0.52	$-0.22	-	-
Basic Shares Outstanding	-	-	-	-	-	-	-	-
Shares Outstanding	-	-	-	-	-	-	-	-
Basic EPS	-	-	-	-	-	-	-	-
EPS - Earnings Per Share	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30
Net Income/Loss	$-2.08	$-1.44	$-0.92	$-1.33	$-1.15	$-0.25	-	-
Total Depreciation And Amortization - Cash Flow	$0.19	$0.24	$0.17	$0271700	$0241700	$0337400	-	-
Change In Accounts Receivable	$0.10	$-0.29	$-0.18	$0.05	$-0.01	$0285000	-	-
Change In Inventories	-	-	-	-	-	-	-	-
Cash Flow From Operating Activities	$-1.67	$-1.08	$-1.47	$-1.51	$-0.68	$-0.33	-	-
Cash Flow From Investing Activities	$0.89	$-0.05	$-0.15	$-0.01	$-0.01	$-0.01	-	-
Debt Issuance/Retirement Net - Total	$-0.15	$-0.60	$-0.08	$-0.08	$0.03	$0.42	-	-
Total Common And Preferred Stock Dividends Paid	-	-	-	-	-	-	-	-
Financial Activities - Other	-	-	$-0.13	$-0.13	$-0.43	$-0.06	-	-
Cash Flow From Financial Activities	$-0.03	$2.68	$1.81	$0.10	$2.65	$0.37	-	-
Net Cash Flow	$-0.81	$1.54	$0.19	$-1.42	$1.97	$0.04	-	-
Common Stock Dividends Paid	-	-	-	-	-	-	-	-